The funding is intended to enable companies in the commercial sector to carry out fundamental research and development work in the field of modern biotechnology and genetic engineering and to enable or accelerate the translation of research and development results in modern biotechnology and genetic engineering into new products, new processes, new technologies and new knowledge-based services.
Funding covers the following topics and issues in particular:
- Research and development of bioprocess technologies,
- Research and development of biotechnological production processes, including for biofuels or basic materials for the chemical industry,
- Research and development of technical enzymes and biocatalysts as well as new biomaterials,
- Research and development of mechanisms of action,
- Research and development of active ingredients, vaccines and diagnostics,
- Research and development of technology platforms, especially in the above-mentioned focus areas.
Priority is given to research and development projects that are embedded in a growth-oriented corporate strategy.
Recipients of funding
Eligible applicants are
- Companies with their registered office or branch in the Free State of Bavaria,
- non-university research institutions as well as state universities and institutions of state universities in Bavaria,
- other applicants with their registered office or branch office in the Free State of Bavaria who have the technical qualifications and sufficient capacity to successfully complete the tasks described in the project.
The research, development and innovation (R&D&I) projects must be carried out in close cooperation between several companies from the commercial sector or between such companies and research institutions. Several partners along the value chain should cooperate. Preference will be given to small and medium-sized enterprises (SMEs).
The following are eligible for funding
- Personnel costs (flat rates),
- Costs for instruments and equipment,
- costs for contract research, technical knowledge and for patents acquired directly or under license from third parties, as well as costs for consulting and equivalent services used exclusively for the research and development project,
- other operating expenses (materials, supplies, etc.) incurred directly as a result of the research and development activity.
Type and scope
The funding is provided in the form of grants as part of project funding.
The aid intensity is
- Up to 50 percent of the eligible costs of the project or feasibility study in the case of industrial research,
- up to 25 percent of the eligible costs of the project or feasibility study in the case of experimental development.
In the case of collaborative projects, the aid intensity is determined for each individual beneficiary; the maximum aid intensity for the collaborative project is 50 percent. In addition, up to 15 percentage points may be granted to industrial project partners if the conditions of Article 25(6)(b) of the GBER are met.
If different project activities can be assigned to both industrial research and experimental development, the funding rate will be determined on a pro rata basis.